Lemelson-MIT Prize Honors
Feng Zhang, MIT
November 7, 2017 | EmTech
Presented by the Lemelson-MIT Program
Feng Zhang, Professor, Investigator, MIT
Feng Zhang is a pioneer of the revolutionary CRISPR gene-editing technology, as well as TAL effectors and optogenetics. Zhang and his team were first to develop and demonstrate successful methods for using an engineered CRISPR-Cas9 system to edit genomes in living mouse and human cells, and they have turned CRISPR technology into a practical and shareable collection of tools for robust gene editing among academic researchers worldwide.
Zhang is a core member of the Broad Institute of MIT and Harvard, an investigator at the McGovern Institute for Brain Research, James and Patricia Poitras Professor in Neuroscience at MIT, and associate professor in the Departments of Brain and Cognitive Sciences and Biological Engineering at MIT. He also cofounded Editas Medicine in 2013, with other leading researchers in genome editing, to translate the promise of genome editing science into a broad class of transformative genomic medicines.
Zhang won the $500,000 Lemelson-MIT Prize in 2017 for his inventions, his commitment to collaboration and mentorship, and his dedication to improving our world through innovative solutions.